Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 1998

View Archived Issues

Possible therapeutic strategy for atherosclerosis: interruption of CD40 signaling

Platelet activity after coronary thrombolysis with reteplase and alteplase

SQ-29548 protects against COX inhibitor-associated postischemic cardiac dysfunction

Novel antiasthmatic TYB-2285 reported to inhibit late asthmatic response and histamine release

Rights to rhFIX gene for use in gene therapy available from BTG

Wyeth-Ayerst to market Abelcet in Greece

Ergo Science completes enrollment of phase II Ergoset clinical study for obesity

Texas Biotechnology reports additional positive phase IIa trial results for TBC-11251

Inhibitor of IgE antibody production discovered by Asahi Chemical

Aronex expands clinical development program for Atragen

Gelatinase inhibitors in development by Kotobuki

Bronchodilators with a pyrrolopyrazolopyrimidine structure patented by Pola

Novavax extends option agreement with Cantab

Dainippon claims series with potential for urinary incontinence

Protein farnesyltransferase inhibitors from Kyowa Hakko

Roche: Q2 1998 highlights

Potassium channel-blocking immunosuppressants from Merck & Co.

KRH-594: profile of a new angiotensin II receptor antagonist

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...